CL2011000589A1 - Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. - Google Patents

Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.

Info

Publication number
CL2011000589A1
CL2011000589A1 CL2011000589A CL2011000589A CL2011000589A1 CL 2011000589 A1 CL2011000589 A1 CL 2011000589A1 CL 2011000589 A CL2011000589 A CL 2011000589A CL 2011000589 A CL2011000589 A CL 2011000589A CL 2011000589 A1 CL2011000589 A1 CL 2011000589A1
Authority
CL
Chile
Prior art keywords
cancer
treatment
pharmaceutical composition
pyrrolidin
carboxamide
Prior art date
Application number
CL2011000589A
Other languages
English (en)
Inventor
Zhuming Zhang
Qingjie Ding
Jin-Jun Liu
Nan Jiang
Tina Morgan Ross
Jing Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2011000589A1 publication Critical patent/CL2011000589A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN DIVULGA COMPUESTOS DE LA FÓRMULA (I): DONDE X, Y, R1, R2, R3, R4, R5, R6 Y R7 TIENEN LOS SIGNIFICADOS DESCRITOS EN EL PLIEGO DE REIVINDICACIONES; LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS; COMPOSICIÓN FARMACÉUTICA QUE INCLUYE A DICHOS COMPUESTOS, Y EL USO DE DICHA COMPOSICIÓN Y COMPUESTOS EN EL TRATAMIENTO DEL CÁNCER.
CL2011000589A 2008-09-18 2011-03-18 Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. CL2011000589A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9788408P 2008-09-18 2008-09-18
US22563309P 2009-07-15 2009-07-15

Publications (1)

Publication Number Publication Date
CL2011000589A1 true CL2011000589A1 (es) 2011-08-12

Family

ID=41402151

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000589A CL2011000589A1 (es) 2008-09-18 2011-03-18 Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.

Country Status (29)

Country Link
US (1) US20100075948A1 (es)
EP (1) EP2340021B1 (es)
JP (1) JP5658157B2 (es)
KR (1) KR101380013B1 (es)
CN (1) CN102159207B (es)
AR (1) AR073598A1 (es)
AU (1) AU2009294673B2 (es)
BR (1) BRPI0919325A2 (es)
CA (1) CA2734363C (es)
CL (1) CL2011000589A1 (es)
CO (1) CO6361910A2 (es)
CR (1) CR20110099A (es)
DK (1) DK2340021T3 (es)
EC (1) ECSP11010898A (es)
ES (1) ES2398342T3 (es)
HR (1) HRP20130047T1 (es)
IL (1) IL211167A0 (es)
MA (1) MA32711B1 (es)
MX (1) MX2011002976A (es)
MY (1) MY160424A (es)
NZ (1) NZ591024A (es)
PE (1) PE20110367A1 (es)
PL (1) PL2340021T3 (es)
PT (1) PT2340021E (es)
RS (1) RS52660B (es)
RU (1) RU2506257C2 (es)
TW (1) TWI367207B (es)
WO (1) WO2010031713A1 (es)
ZA (1) ZA201101740B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
CN101898998B (zh) * 2010-08-25 2012-09-19 武汉武药科技有限公司 一种盐酸替罗非班中间体的制备方法
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
WO2012076513A1 (en) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
SG11201406889WA (en) * 2012-05-30 2015-02-27 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
HK1215453A1 (zh) 2013-07-03 2016-08-26 豪夫迈．罗氏有限公司 用於将用mdm2拮抗剂进行患者癌症治疗个人化的基於mrna的基因表达
EP3131544B1 (en) 2014-04-17 2018-12-12 The Regents of the University of Michigan Mdm2 inhibitors and therapeutic methods using the same
EP3260119B1 (en) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Combination method for treating cancer
US10485794B2 (en) 2015-04-13 2019-11-26 Daiichi Sankyo Company, Limited Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
EP3527226A4 (en) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
KR102122469B1 (ko) 2016-11-01 2020-06-12 주식회사 엘지화학 변성 공액디엔계 중합체 및 이의 제조방법
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
US11981664B2 (en) 2018-10-03 2024-05-14 Rijksuniversiteit Groningen Photoresponsive nutlin derivatives and uses thereof
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
AU2006216780B8 (en) * 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
CA2656398A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof

Also Published As

Publication number Publication date
ZA201101740B (en) 2013-08-28
RU2506257C2 (ru) 2014-02-10
CO6361910A2 (es) 2012-01-20
HK1160399A1 (en) 2012-08-17
DK2340021T3 (da) 2012-12-10
ECSP11010898A (es) 2011-04-29
ES2398342T3 (es) 2013-03-15
RU2011115111A (ru) 2012-10-27
HRP20130047T1 (hr) 2013-02-28
EP2340021B1 (en) 2012-11-07
WO2010031713A1 (en) 2010-03-25
AR073598A1 (es) 2010-11-17
MX2011002976A (es) 2011-04-11
TWI367207B (en) 2012-07-01
CR20110099A (es) 2011-04-04
AU2009294673B2 (en) 2014-08-14
AU2009294673A1 (en) 2010-03-25
CA2734363C (en) 2016-10-25
PT2340021E (pt) 2013-01-25
CN102159207A (zh) 2011-08-17
JP2012502940A (ja) 2012-02-02
PE20110367A1 (es) 2011-06-13
BRPI0919325A2 (pt) 2021-03-30
KR20110040989A (ko) 2011-04-20
RS52660B (sr) 2013-06-28
CN102159207B (zh) 2015-02-04
PL2340021T3 (pl) 2013-04-30
MY160424A (en) 2017-03-15
JP5658157B2 (ja) 2015-01-21
TW201012798A (en) 2010-04-01
EP2340021A1 (en) 2011-07-06
KR101380013B1 (ko) 2014-04-10
IL211167A0 (en) 2011-04-28
NZ591024A (en) 2013-01-25
CA2734363A1 (en) 2010-03-25
MA32711B1 (fr) 2011-10-02
US20100075948A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30759A1 (es) Compuestos quimicos
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
NI201100130A (es) Derivados de pirimidin indol para el tratamiento de cáncer.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
UY32203A (es) Amino pirimidinas y su uso en terapia
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY35275A (es) Derivados de aminopirazina
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
UY31141A1 (es) Compuestos de piperidina y sus usos
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου